Network Analysis of a -Mouse Model of Autosomal Dominant Polycystic Kidney Disease Identifies HNF4α as a Disease Modifier

Autosomal Dominant Polycystic Kidney Disease (ADPKD; MIM ID's 173900, 601313, 613095) leads to end-stage kidney disease, caused by mutations in PKD1 or PKD2. Inactivation of Pkd1 before or after P13 in mice results in distinct early- or late-onset disease. Using a mouse model of ADPKD carrying floxed Pkd1 alleles and an inducible Cre recombinase, we intensively analyzed the relationship between renal maturation and cyst formation by applying transcriptomics and metabolomics to follow disease progression in a large number of animals induced before P10. Weighted gene co-expression network analysis suggests that Pkd1-cystogenesis does not cause developmental arrest and occurs in the context of gene networks similar to those that regulate/maintain normal kidney morphology/function. Knowledge-based Ingenuity Pathway Analysis (IPA) software identifies HNF4α as a likely network node. These results are further supported by a meta-analysis of 1,114 published gene expression arrays in Pkd1 wild-type tissues. These analyses also predict that metabolic pathways are key elements in postnatal kidney maturation and early steps of cyst formation. Consistent with these findings, urinary metabolomic studies show that Pkd1 cystic mutants have a distinct profile of excreted metabolites, with pathway analysis suggesting altered activity in several metabolic pathways. To evaluate their role in disease, metabolic networks were perturbed by inactivating Hnf4α and Pkd1. The Pkd1/Hnf4α double mutants have significantly more cystic kidneys, thus indicating that metabolic pathways could play a role in Pkd1-cystogenesis.

Published in the journal: . PLoS Genet 8(11): e32767. doi:10.1371/journal.pgen.1003053
Category: Research Article
doi: 10.1371/journal.pgen.1003053


Autosomal Dominant Polycystic Kidney Disease (ADPKD; MIM ID's 173900, 601313, 613095) leads to end-stage kidney disease, caused by mutations in PKD1 or PKD2. Inactivation of Pkd1 before or after P13 in mice results in distinct early- or late-onset disease. Using a mouse model of ADPKD carrying floxed Pkd1 alleles and an inducible Cre recombinase, we intensively analyzed the relationship between renal maturation and cyst formation by applying transcriptomics and metabolomics to follow disease progression in a large number of animals induced before P10. Weighted gene co-expression network analysis suggests that Pkd1-cystogenesis does not cause developmental arrest and occurs in the context of gene networks similar to those that regulate/maintain normal kidney morphology/function. Knowledge-based Ingenuity Pathway Analysis (IPA) software identifies HNF4α as a likely network node. These results are further supported by a meta-analysis of 1,114 published gene expression arrays in Pkd1 wild-type tissues. These analyses also predict that metabolic pathways are key elements in postnatal kidney maturation and early steps of cyst formation. Consistent with these findings, urinary metabolomic studies show that Pkd1 cystic mutants have a distinct profile of excreted metabolites, with pathway analysis suggesting altered activity in several metabolic pathways. To evaluate their role in disease, metabolic networks were perturbed by inactivating Hnf4α and Pkd1. The Pkd1/Hnf4α double mutants have significantly more cystic kidneys, thus indicating that metabolic pathways could play a role in Pkd1-cystogenesis.


Autosomal Dominant Polycystic Kidney Disease (ADPKD; MIM ID's 173900, 601313, 613095) is the most common genetic cause of polycystic kidney disease (PKD), with an estimated prevalence of approximately 1∶1000 [1]. ADPKD is caused by mutations in PKD1 (∼85%) or PKD2 (∼15%), which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Morphologically, the disease is characterized by the gradual replacement of normal kidney parenchyma by fluid-filled cysts [2]. Though 15 years have elapsed since the identification of PKD1 and PKD2 and despite intense effort focused on determining the function of their respective gene products, the pathways and mechanisms by which PC1 and PC2 regulate luminal diameter remain poorly understood.

To better model the disease in rodents and determine how acquired Pkd1 inactivation results in cyst formation, we had developed a novel mouse line with floxed alleles of Pkd1 that could be conditionally inactivated in a large proportion of kidney cells at distinct timepoints [3], [4]. We used this line to determine that Pkd1 inactivation prior to P12 results in cyst formation within 7–21 days, whereas inactivation on or after P14 results in cyst formation only after 4–5 months [4]. This effect is associated with changes in gene expression patterns that take place between P12 and P14 in wild-type kidneys. Other groups have similarly identified developmental windows in which inactivation of Pkd1 [5] or other cystogenes (Kif3a and Tg737 [6], HNF-1β [7]) leads to early- or late-onset cyst development. These observations suggest that pathways related to kidney maturation play relevant roles in rapid cyst formation.

The existence of a functional maturation phase in postnatal kidney was postulated over 50 years ago, when physiologists observed that the composition and volume of urine excreted by newborn animals, when compared to adults, tended to vary less in response to osmotic stress [8]. Subsequent studies linked some of these changes to intrinsic renal postnatal events, such as changes in expression patterns of tight junction proteins or transporters [9], [10]. However, the pathways responsible for postnatal kidney maturation and how they relate to the maintenance and establishment of kidney architecture remain unknown. The current study tackles this issue by analyzing mRNA, microRNA and urinary metabolomics during the early stages of cyst formation and kidney maturation in control and mutant animals induced before P10. To our knowledge, this is the first study to focus on this short time interval and characterize the interplay between these two phenomena. Our results suggest that there is no developmental arrest in PKD kidneys, but that metabolic and HNF4α-related pathways involved in kidney maturation are modifiers of cystogenesis. This finding was confirmed by showing that double knockout of Hnf4α and Pkd1 significantly worsens cystic disease.


Metabolic Pathways Could Underlie Kidney Maturation and Determine the Susceptibility to Rapid Cyst Formation in the Early-Onset Model of ADPKD

A total of 70 kidneys [36 Pkd1cko/cko;tamoxifen-cre positive (mutant) and 34 Pkd1cko/cko;tamoxifen-cre negative (control)] in which Pkd1 knockout was induced between P5 and P9 were harvested between P11 and P24 and analyzed using gene expression arrays. This set includes mutant kidneys with variable degrees of cystic transformation. In fact, animals induced at P7 display mostly normal histology at P12 (6 normal and 11 with dilated tubes) and are cystic at P14 (4 dilated and 14 grossly cystic; Figure 1A). Consistent with our previous data showing high rates of Pkd1 inactivation in this model [4], mutant kidneys are enlarged and globally cystic at later time points.

Histology and gene expression patterns in early-onset model.
Fig. 1. Histology and gene expression patterns in early-onset model.
A) Representative kidney histology (H&E stain; scale bar: 500 mm); B) PCA plot: genotype and age explain most of the clustering in the complete set of 70 kidneys in the early-onset model (control: red; mutant: blue; size of spheres: age). C and D) Heatmap plot of mutant-signature (genes in Table S1) in the test (C) and validation (D) groups. E) Heatmap plot of ME2 (genes in Table S3) cluster in the validation group.

A subset of 32 P12 and P14 mutant and control samples was used for bioinformatics analysis (test group), and the results were validated using the remaining samples (validation group). Principal component analysis (PCA) plots show that clustering correlates with genotype and age in the test group (Figure 1B). Statistical analysis shows that few genes (48 probes; fold change>1.2 and fdr-adjusted p<0.05) are different between mutants and controls at P12, but that over 600 genes (622 probes; fold change>1.2 and fdr-adjusted p<0.05) are differentially expressed at P14. To enrich for genes differentially expressed at the early stages of cyst formation, we focused on the subset that had some evidence of differential expression at P12 (i.e. either fold change>1.2 or fdr-adjusted p<0.05) and that fulfilled both criteria at P14 (i.e. fold change>1.2 and fdr-adjusted p<0.05). This yields a mutant-signature of 87 genes (Table S1). Most of these genes are up-regulated in mutants, with higher expression levels in cystic (P14) animals (Figure 1C). The mutant-signature also clusters mutant and control mice in the validation group (Figure 1D). Gene ontology (GO) classification suggests that the mutant-signature is significantly enriched in categories related to cell differentiation (3.64E-05), tissue remodeling (5.75E-05), and a variety of developmental and metabolic processes (E-04 and E-03) (Table S2).

One surprising result was the small number of genes with changes greater than 50%. Despite this finding, the expression patterns in mutant and control groups are sufficiently different to cluster most samples according to genotype, suggesting many small, but genotype-specific, differences. Weighted gene co-expression network analysis (WGCNA) is an approach particularly well suited for such situations. WGCNA can be used to identify clusters of genes with similar patterns of expression across a set of microarray samples rather than individual, differentially expressed genes [11]. The approach provides various features that can be used to cluster closely related patterns into a small number of distinct modules, each of which can be summarized by its first principal component (module eigengene), which can then be associated with genotype, developmental state or phenotypic traits. The greatly reduced number of variables also simplifies the analyses by minimizing the multiple testing problem. Using WGCNA, one can create a connectivity matrix that models gene networks with hubs, a condition likely met by biological networks [12].

We therefore used WGCNA to analyze our dataset. Calculating the correlation between module eigengenes and genotypes, we identified one significantly correlated cluster (ME2, 629 genes, correlation: 0.81, p = 2.5E-08; Table S3). Of the 629 genes in ME2, 67 are part of the mutant-signature described above (overlap p = 6.0E-20). Furthermore, this cluster distinguishes mutant and control groups also in the validation set of samples (Figure 1E). The ME2 cluster also was enriched for multiple GO categories related to development (E-08), cell differentiation, anatomical structure morphogenesis (E-07), and metabolic pathways E-04; Table S4). Additional pathway analysis using the knowledge-based Ingenuity Pathway Analysis (IPA) software suggested that several genes in both ME2 and the mutant signature gene sets not only belong to metabolic functional groups but are also connected to/via HNF4α, a transcription factor involved in the regulation of several metabolic and developmental pathways [13] (Figure 2A). Interestingly, other nodes previously implicated in PKD, such as Tumor Necrosis Factor (TNF) [14], angiotensinogen (AGT) [15] and arginine vasopressin (AVP) [16] were also identified in this network.

Metabolic pathways could underlie kidney maturation and determine the susceptibility to rapid cyst formation in the early-onset model of ADPKD.
Fig. 2. Metabolic pathways could underlie kidney maturation and determine the susceptibility to rapid cyst formation in the early-onset model of ADPKD.
A) Knowledge-based IPA network (score: 24) using genes in early-onset mutant-signature (genes in Table S1). HNF4α(blue arrow) is a node (green/red: genes down/up-regulated in P12 mutant kidneys; solid lines: direct interactions; dashed lines: indirect interactions). B) Dendrograms of module eigengenes showing blocks of correlated eigengenes (meta-modules: in rectangles) suggest that gene correlation networks are preserved in mutant animals but change during P12 to P14 kidney maturation. The metabolism-related MEturquoise cluster (arrow; genes in Table S5) is part of meta-module at P12 but not at P14.

Gene Correlation Networks Are Preserved in Mutant Animals

To further analyze the link between kidney maturation and early stages of cyst formation, consensus gene modules (i.e. clusters of genes that are highly connected in each of the four experimental groups: (P12/P14) x (mutant/control)) were identified using WGCNA. Correlations between module eigengenes were then calculated for each experimental group [17]. The analysis of the preservation of the correlation between module eigengenes across different biological conditions has been proposed as a measure of similarity between gene networks [18], and in theory allows one to determine if changes in gene expression patterns are due to changes in gene networks, or to changes in the levels of expression within conserved gene networks.

Our data yield a high degree of preservation between the various gene modules across all conditions (preservation values: 0.88 to 0.92), suggesting no major network changes. In addition, using a dendrogram to depict eigengene correlations, sets of highly correlated eigengenes (i.e. meta-modules) can be readily visualized (Figure 2B) and are mostly preserved between mutant and controls. However, the turquoise module (Table S5), which is highly correlated with the pink/blue/yellow/red modules at P12, is less correlated at P14, both in mutants and controls (Figure 2B). These data suggest the surprising result that the major change in how the gene networks are inter-related in our model is not due to Pkd1 inactivation, but rather due to changes that occur normally between P12 and P14. They also imply that the transcriptional networks activated during normal kidney maturation are also deployed in the mutant kidney, which, our data suggest, mature normally. These data are also consistent with the PCA plot in Figure 1B, which separated P12 and P14 animals.

Given the striking difference in the susceptibility to the effects of Pkd1 inactivation before or after P13, it is therefore likely that the biological processes modulated by genes in the turquoise module are important modifiers of PKD. Gene ontology classification suggests that MEturquoise is almost exclusively enriched for metabolic pathways (top hit, generation of energy, p-2.57E-21; Table S6). Taken together with the enrichment of metabolic pathways in disease-specific gene sets (ME2 and mutant signature), our data are consistent with a role of the metabolic contexts in determining the switch from early- to late-onset cystic disease in this Pkd1 model. These findings suggest the unintuitive result that metabolic, rather than developmental, pathways are responsible for the dramatic change in susceptibility to Pkd1 inactivation in P12 vs. P14 mice.

No Evidence of MicroRNA Changes in Pkd1 Mutant Kidneys

MicroRNA's are thought to play an important role in fine-tuning gene expression and have been reported relevant for kidney development [19] and PKD [20], [21]. Therefore, it seemed reasonable to suppose they could be involved in orchestrating the observed gene expression changes. We analyzed 47 samples using Agilent microRNA arrays spanning the P12/P14 mutant and control groups (Table S7) and failed to identify differences (fdr p value<0.05). No differences were found by real-time quantitative PCR in a set of 3 microRNA's previously linked to cystic disease (mir15a, mir21 and mir31 [20], [22]; Figure 3).

No evidence for distinct microRNA expression patterns.
Fig. 3. No evidence for distinct microRNA expression patterns.
A) PCA plot of microRNA expression covariance matrix showing absence of clustering according to mutant- or age-specific patterns (microRNAs in Table S7). B to D) Plots of fold-change (to control) of RT-PCR data showing similar expression levels of mir-15a (B), mir-21 (C) and mir-31 (D; P14 control kidneys: 5 samples, 4 replicates each; P14 mutant kidneys: 6 samples, 4 replicates each).

Meta-Analysis of Published Gene Array Data of Pkd1 Wild-Type Tissues Identifies Gene Modules Likely Involved in Kidney Maturation and Cyst Formation

If, as our data suggest, the gene expression changes in Pkd1 mutants are not due to major re-wiring of gene networks, it seems reasonable to suppose that modules of genes normally co-regulated in distinct biological conditions (such as different organs, developmental stages, or activation status of signaling pathways) might also be co-regulated in Pkd1 mutants. As a consequence, such modules, when enriched for genes differentially expressed in Pkd1 mutants, could uncover pathways likely disrupted in mutant animals. To test this, 1114 microarray experiments surveying various biological conditions were downloaded from the Gene Expression Omnibus (GEO; repository, and analyzed using WGCNA (Table S8). Of the 49 gene modules thus obtained (Table S9), two had significant overlap with the mutant signature set (Modules 5 and 17, p<0.001, Table S10). Alternatively, ranking these modules according to how accurately they predict (mutant x age) status in the test dataset, module 17 had the lowest misclassification rate, clustering only one of the mutants with the controls (and none of the controls with mutants; Figure 4). Consistent with the results described in the previous sections, gene ontology analysis showed enrichment for metabolic pathways (Module 5, p = 1.82E-97; Table S11), cell adhesion and organ morphogenesis (Module 17, p = 1.59E-32 and 3.26E-11; Table S12). Furthermore, enrichment for HNF4α-pathways (nuclear receptor subfamily 1, group H, member 4; p = 3.3E-05) was again observed. Analogous analysis searching for modules with enrichment for genes that change with the normal P12 to P14 transition identifies modules 5 and 17 as the most significant gene clusters (Table S10), further suggesting that similar transcriptional programs are involved in both early stages of cyst formation and postnatal maturation.

Meta-analysis of 1,114 gene expression arrays identifies gene clusters differentially expressed in <i>Pkd1</i> mutant kidneys.
Fig. 4. Meta-analysis of 1,114 gene expression arrays identifies gene clusters differentially expressed in Pkd1 mutant kidneys.
PCA plot showing that module 17 separates mutant and control groups along the second principal component in both test (A) and validation (B) groups (meta-analysis genes in Table S9).

HNF4α Is a Modifier of Pkd1-Cystogenesis

The independent identification of HNF4α as a relevant transcription node using various strategies suggested that it could play a role in Pkd1-cystogenesis. In fact, work in our lab had previously shown increased HNF4α activity in Pkd1 null placentas and kidneys [23]. To further probe the role of metabolic pathways in general, and HNF4α in particular, in Pkd1-cystogenesis, Pkd1cko mice were bred to Hnf4αcko mice. Gene knockout was induced at P7, and the animals were harvested between P12 and P21. Analyzing kidney/body weight and cystic index between P19 and P21 in a set of 46 cre positive Pkd1cko/cko animals (8 Hnf4αcko/cko; 23 Hnf4αcko/wt; 15 Hnf4αwt/wt), our results suggest that the presence of HNF4α has a significant protective effect on cyst formation (Figure 5). Despite the variability in phenotype, the 95% confidence interval suggests a reduction of between 5 and 63% in the kidney/body weight (p = 0.023), and between 10 and 67% in cystic index (p = 0.013), an effect similar to that reported with the use of metformin, a metabolism-altering drug [24].

<i>Hnf4α</i> is a modifier of <i>Pkd1</i>-cystogenesis.
Fig. 5. Hnf4α is a modifier of Pkd1-cystogenesis.
(A) Representative kidney histology of Pkd1cko/cko; Hnf4αcko/cko; Tamoxifen-Cre+ (left) and Pkd1cko/cko; Hnf4αwt/wt; Tamoxifen-Cre+ (H&E stain; scale bar: 1000 mm). (B and C) Boxplot of kidneys/(2*body weight) (B; 95% confidence interval: 0.0021 to 0.0245, p = 0.02271) and cystic index (C; 95% confidence interval: 0.0334 to 0.2304, p = 0.01311; blank squares: samples).

Urinary Metabolomics Shows Altered Metabolic Profile in Mutant Animals

Metabolic changes in the urine of 84 animals, ranging from P12 to P21, were assessed using ultraperformance liquid chromatography followed by quadrupole time-of-flight mass spectrometry (UPLC/QTOFMS). Principal component analysis suggests that Pkd1cko/cko cystic mutants have a distinct profile of excreted metabolites, irrespective of Hnf4α genotype (Figure 6A). A set of 1458 mass spectra (528 electrospray ionization (ESI) positive, Table S13; 930 ESI negative, Table S14; mean>0.1 in both mutant and control groups, fdr-p<0.02, fold change>2) were differentially detected between control and mutants, 84 of which could be mapped to KEGG ids recognized by IPA (54 of which were unique identifiers in KEGG pathways; Table S15), and were used for further pathway analysis. The results suggest altered activity in several metabolic pathways (Table 1 and Table S16), including purine and tyrosine metabolism. Tyrosine metabolites are known to cause kidney injury, and at least one mouse model of hepatorenal tyrosinemia shows evidence of altered cAMP signaling [25], a pathway thought to be involved in PKD [16], [26], [27].

Urinary metabolomics shows distinct patterns in cystic versus control mice.
Fig. 6. Urinary metabolomics shows distinct patterns in cystic versus control mice.
(A) PCA plot of positive mass spectra identified in urine (Table S13), showing separation of control and Pkd1 mutant samples, irrespective of Hnf4α genotype, along the first principal component. (B) Normalized levels of acetylcarnitine in urine samples of Pkd1/Hnf4α mice at different ages. (C) MS/MS fragmentation spectra of acetylcarnitine authentic standard versus a representative urine sample.

Tab. 1. Metabolic pathways significantly different in the urine of mutant mice.
Metabolic pathways significantly different in the urine of mutant mice.

Using partial least squares, urinary acetylcarnitine was identified as the metabolite that most accurately predicts mutant status, with levels higher in mutants at all time points (Figure 6B). Verification of acetylcarnitine was obtained by comparing fragmentation patterns of urine samples with authentic standard by tandem mass spectrometry (Figure 6C). Increased concentrations of l-carnitine and acylcarnitines have been described in patients with disorders of organic acid metabolism [28], pathologies that also manifest polycystic kidneys [29]. Taken together, these results are consistent with the observed changes in metabolic pathways playing a role in modulating cystogenesis.


A handful of studies have previously examined gene expression changes in human and mouse renal cystic tissue. While they have reported interesting differences that affect multiple signaling pathways, they have a number of important limitations that greatly reduce their informativeness. In the case of human ADPKD, two studies have described global gene expression changes in Pkd1-related cyst formation using cells derived from non-cystic/cystic human kidneys [30], [31]. In one, the investigators performed SAGE analysis of four immortalized cell lines derived from normal and cystic biliary epithelial cells (N = 1 each) and normal and cystic renal epithelial cells (N = 1 each). Top differentially expressed genes (N = 250) were selected for a custom array that was then used to query gene expression in eight cystic kidneys removed from individuals with end stage kidney disease and six undefined “normal” kidneys. Only ∼50% of the genes had detectable signal above background in this set of specimens, and differential expression was detected for 74. The SAGE and chip patterns were discordant for 12 of the 74 genes.

The second study compared gene expression levels in a total of 13 cysts (grouped into three sizes) from five cystic kidneys along with a “minimally” cystic renal cortical specimen from each specimen to gene expression levels in three non-cancerous “normal control” specimens excised from the renal cortex of three nephrectomized kidneys with isolated renal cell carcinoma. The study did not provide any details about the cell-type composition of the cyst (ie. isolated cyst-lining epithelial cells vs. excised cysts which include both epithelial and non-epithelial cell components).

There are a number of other important considerations relevant for both studies: 1) the number of individuals that was studied was small; 2) experimentally relevant details were not provided for the control groups; 3) when using cystic vs. “control” cell lines extracted from ADPKD patients, defining relevant control lines is a major challenge as cysts arise from various nephron segments; 4) differences may be idiosyncratic to individuals or clones and hard to generalize; 5) cysts from end-stage kidneys may have gene expression patterns that are secondary to the cystic stage or uremic state and not necessarily part of Pkd1-related pathways.

There also have been two studies of Pkd1 mutant mouse models. Chen et al. used a hypomorphic model to track changes in gene expression over the course of the first 3.5 weeks of life (four time points, N = 13 pairs) as the kidney progresses from a globally microcystic to a macrocystic stage [32] and Pandey et al. focused on embryonic kidneys, analyzing Pkd1 null and control kidneys at E14.5 and E17.5 (N = 3 at each time point) [21]. Both studies have methodologic issues that complicate their interpretation. In the case of the Chen study, analysis of the raw data suggests the presence of one outlier (GSM339412) and at least one sample likely with hybridization artifacts (GSM339408; background higher than signal in one channel, and undetected in the other), and it is unclear how/if they affect the reported results. In the case of Pandey et al, most of the analyses were performed using an uncorrected p-value. When we repeated the analyses using their dataset (GSE24532) and corrected for multiple comparisons, very few probes were significantly differentially expressed (File S1). In fact, some of the genes reported as differentially expressed between mutant and control E14.5 animals seemed to have expression values below background, and high detection p-values, suggesting that their fluctuations could be experimental noise, rather than true biological differences. When we re-analyzed the data keeping only probes with detection p-value<0.01 in all samples, the number of differentially expressed genes between mutants and controls at E14.5 or E17.5 was dramatically reduced, and Gene Set Enrichment Analysis failed to run due to the small number of differentially expressed genes.

Our study has a number of unique features that distinguish it from the others. First, we targeted a poorly understood postnatal renal maturation stage that we had previously shown plays a critical role in determining the rate of cyst formation in response to acquired Pkd1 inactivation. Second, we compared gene expression patterns from both pre-cystic and early cystic specimens and correlated them to transcriptional programs activated during this late stage of kidney maturation. Third, we used a large number of homogeneous samples, thereby minimizing both biological and experimental noise. Importantly, using rigorous correction for multiple comparisons, we identified a modest number of small, but significant, gene expression changes. Finally, we confirmed our findings in a second, large validation set of specimens that covered a wider temporal window. The profile generated using the test group properly clustered the validation set of specimens.

One important goal of our study was to try to identify transcriptional networks responsible for the cystic state. Using WGCNA to examine co-expression networks, we were surprised to find similar architecture in both mutant and controls. We then extended the study to include meta-analysis of 1114 gene expression arrays that sampled a variety of tissues and biological conditions and obtained similar results. In fact, they suggest that some modules of co-regulated genes are preserved across distinct biological conditions, including Pkd1 inactivation, and that transcriptional regulation of a few of these modules is responsible for a large fraction of the gene expression changes observed in Pkd1 mutants. They also provide proof of principle that one can mine databases for clusters of co-regulated genes overlapping with small sets of disease-signature genes to uncover relevant pathways. Finally, these results lead us to speculate that PKD pathogenesis might share some characteristics with biological processes such as ageing, in which the compounding of small changes, rather than few, major differences, determines the phenotype. However, as the mechanisms linking these changes to PC1 remain unknown, it is theoretically possible that a major hub downstream of PC is responsible for all subsequent changes.

Complementing the WGCNA approach, we used knowledge-based network tools to identify from the set of mutant signature genes candidate biological networks with altered activity. One of the advantages of a network-based approach to studying disease is that it identifies key molecules at nodes that may play important roles in modulating disease initiation and progression. Interestingly, we found that a number of the nodes had previously been linked to polycystic kidney disease (TNF, AGT, AVP). For example, TNF-αwas reported to trigger cyst formation in both wild-type and Pkd2+/− kidney organ cultures [14], suggesting a role for inflammatory pathways in cyst growth. The renin-angiotensin system (AGT) has been reported to accelerate disease progression by enhancing fibrosis and promoting cyst growth [15]. The AVP/vasopressin receptor signaling pathway is thought to promote cystic disease by increasing cAMP levels, which then are thought to promote fluid secretion via PKA-dependent chloride-channels and cystic epithelial cell growth via activation of B-Raf/ERK pathway [27]. Two clinical trials are currently underway testing the hypothesis that drugs which modulate the AGT and AVP nodes will slow progression of disease ( HALT PKD NCT00283686; TEMPO 3/4 NCT00428948).

In the current study, we focused on HNF4α because we had multiple lines of evidence implicating the protein in Pkd1 cystogenesis. As noted elsewhere, we had previously reported altered HNF4α activity in Pkd1 null placentas and kidneys [23]. Our present data are consistent with those observations, showing significant enrichment for genes linked to metabolic pathways in our mutant signature set and in disease-associated eigengenes. Our metabolomics data further support this connection. HNF4α also was identified by IPA as one of the most highly connected nodes with the most direct links. Therefore, we perturbed the network map by inactivating Hnf4α in the context of Pkd1 inactivation and found that HNF4α in fact plays an important modulatory role in the early onset Pkd1 cyst model. Given that our studies independently identified three nodes previously implicated as important pathway factors in PKD and predicted a fourth that we confirmed with genetic manipulation of the gene, we postulate that some of the other nodes may also be important disease modifiers (ie. nitric oxide synthase 1 (NOS1), superoxide dismutase 2 (SOD2), SHC-transforming protein (SHC1)). It is perhaps relevant that both SOD2 and SHC1 have a role in regulating mitochondrial activity and response to oxidative stress. Further study will be required to test this hypothesis.

HNF4α is a transcription factor with complex, possibly inter-related functions in the regulation of developmental programs, maintenance of organ differentiation and regulation of metabolic pathways. In the developing embryo and fetus, it plays a critical role in epithelial morphogenesis. Homozygous germline inactivation results in early embryonic demise [33]. Bypassing this lethal stage by tetraploid rescue or conditional inactivation strategies, investigators have shown that Hnf4α also is essential for liver and colon development [34][37]. In post-developmental organs, inactivation of Hnf4α has more subtle, functional effects [38], [39]. Post-partum inactivation of Hnf4α in the liver results in fatty livers and altered serum levels of cholesterol, triglycerides, and bile acids whereas inactivation in the colon results in an intact organ with increased susceptibility to injury. Possibly linked to both its developmental and post-developmental roles is HNF4α's key function as a regulator of several metabolic pathways [40], [41]. It may act as a nutritional sensor [36], [40][42] with its function regulated mainly by posttranslational modifications and binding to co-regulators [42]. The possible inter-dependence of the different roles for HNF4α are in part suggested by studies that show that some of the pathologic consequences resulting from its inactivation appear to be non-cell autonomous. Whereas Hnf4α null hepatocytes in vivo lack normal polarity and epithelialization, cultured Hnf4α null cells polarize properly and are indistinguishable from control cells, suggesting that polarity defects might be secondary to abnormal expression of metabolic genes [43].

The role of HNF4α in the kidney is incompletely defined. It is expressed widely in the developing organ and is thought to help regulate mesenchymal to epithelial conversion (MEC) during nephrogenesis [44]. In the adult, Hnf4α is expressed mostly in the cortex, and in proximal tubules, with very low levels of expression in collecting ducts [45]. While no comprehensive analysis of post-natal inactivation of Hnf4α has been reported, in our pilot studies of Pkd1 wild type mice we saw no obvious histologic effects of Hnf4α inactivation in the kidney during the timeframe used in this study (unpublished observation). In contrast, we found that inactivation of Hnf4α in the context of simultaneous Pkd1 inactivation significantly worsened the cystic phenotype. Therefore, we speculate that the paucity of cortical cysts in the early stages of cyst formation, and the increased severity of cystic disease in double Hnf4α/Pkd1 knockout might reflect a protective role of HNF4α. In this scenario, HNF4α activity could be compensatory to Pkd1 inactivation. Alternatively, HNF4αcould be a marker (or driver) of broader metabolic changes, possibly even in other organs (liver), and it is possible that the relevant modifier is the metabolic context, rather than one specific metabolic regulator. According to this model, HNF4α-related changes in metabolic and/or other signaling pathways could change the way cells respond to signals, conferring context-dependent differences in the susceptibility to the effects of Pkd1 inactivation. However, it has to be noted that animals induced after P14 do eventually get cystic (late-onset model), suggesting that changing metabolic contexts may retard, but is unlikely to prevent, disease progression. It also remains to be shown if the same networks/pathways are involved in early- and late-onset Pkd1 disease models.

Urinary metabolomic studies provide additional evidence indicating that dysregulated metabolic pathways may be a property common to multiple forms of PKD. In the current study, we found metabolites of four metabolic pathways significantly different in the urine of early and moderately cystic Pkd1 mutant mice (Table 1). Taylor et al analyzed the urine of female control and minimally cystic jck mice, a mouse model for human nephronophthisis that has a mutation in the murine orthologue of human NPHP9, and found seven metabolic pathways that differed significantly between genotypes [46]. Abbiss et al compared the urine of control and moderately cystic Lewis autosomal recessive polycystic kidney disease rats and found altered levels of 2-ketoglutaric acid, allantoin, uric acid and hippuric acid [47].

Together, these data suggest that metabolic pathways may play an important role in PKD pathobiology. The link between metabolic changes and cell behavior is well recognized in cancer cells, where glycolysis in the presence of oxygen (Warburg effect) and activation of synthesis of substrates for cellular components have long been noticed [48]. In the case of PKD, interpretation of the metabolic differences is more complicated. In late stages of the disease, modest differences in proliferation rate and uremic status may be a confounding factor. However, the transcriptional changes and some of the metabolic differences are observed in minimally cystic animals when proliferation rates are either normal or minimally different. Moreover, the urine samples of moderately cystic mutants in our dataset do not cluster by PCA with those of younger normal mice who have a much higher proliferation rate. In sum, it is unlikely that changes in proliferation rates alone can explain the differences in metabolism. These changes in metabolism may be upstream (or downstream) of several pathways, such as the AMP/ATP-sensing AMP-kinase, or aminoacid-activated mTOR signaling, previously linked to PKD [49]. Our results suggest an alternative explanation for metabolic changes, based on differences in HNF4α activity.

An important question prompted by these observations is whether the observed metabolic effects are the result of the cystic state or a causal factor in promoting cyst growth. We think the data suggest that both answers are true. As noted above, the cysts form contemporaneous with the changes in gene expression, and the altered cellular properties associated with the cystic state likely result in altered cellular metabolism. In this respect, the altered metabolic profile and gene expression patterns may be a consequence of cystic transformation. However, we also show that manipulating Hnf4α activity, and thereby presumably altering the regulation of metabolic gene expression, also modifies the phenotype. This observation suggests that metabolic pathways may be a disease modifier. Future studies will be necessary to determine whether it is the altered activity of metabolic pathways per se or some other functional consequence of Hnf4α activity that is responsible for our findings. It also will be important to determine the most proximal, direct, link between Pkd1 deletion and changes in metabolic pathways.

We have previously shown that proliferation rates drop normally in mutant kidneys induced at P12, and suggested that, assuming proliferation can be used as a marker of developmental status, it was unlikely that Pkd1 deletion induced developmental arrest [4]. Here we show that changes in gene co-expression networks correlate with kidney maturation between P12 and P14 in control animals. Furthermore, we observe very similar network changes in mutant animals during the same interval. WGCNA analysis seems therefore sensitive enough to detect changes in developmental status, and the results imply that mutant kidneys are neither developmentally arrested, nor de-differentiated. It is however likely, given our GO results, that genes normally involved in developmental processes are differentially expressed in mutant kidneys.

Several groups have previously implicated microRNAs in PKD pathogenesis. Using both a comprehensive screening method (microarray) on a large number of specimens and targeted real-time quantitative PCR of a small number of PKD-associated microRNAs on a subset of specimens, we failed to identify significant differences in microRNA expression during the early stages of cyst formation. Several factors could account for these discrepancies: 1) method sensitivity; 2) differentially expressed microRNA's could be cell/model/disease stage-specific; 3) asynchronous waves of microRNA changes may occur in different nephron segments. It is interesting to note, however, that conditional knockout of Dicer in proximal tubules, a nephron segment that becomes cystic when Pkd1 is inactivated, does not result in cystic disease in mice up to 6 months of age, despite microRNA depletion [50] (Dr. Dong, personal communication).

Genes in both the mutant-signature and ME2 module are significantly enriched in gene ontology categories involved in development, which likely reflect the remodeling of nephron segments (anatomical structure development, p = 3.42E-09; cell adhesion, p = 7.87E-09) and surrounding vasculature (vasculature development, p = 1.13E-05). This suggests that additional significant categories such as cell differentiation (p = 9.31E-08) could be related to morphological changes, rather than due to developmental arrest/dedifferentiation, consistent with our results of normal kidney maturation and preservation of gene correlation networks in mutants. Enrichment for metabolic pathways, though also seen in the ME2 cluster (heterocycle metabolic process, p = 3.13E-06; regulation of steroid metabolic process, p = 3.32E-03), is particularly noticeable in the turquoise module, which includes oxidation/reduction (p = 1.16E-14), protein metabolic process (p = 9.12E-09) and glucose metabolism (1.58E-08). As this module seems to be correlated with kidney maturation and possibly to the susceptibility to the effects of Pkd1 deletion, our data highlight the metabolic context as a likely modifier of cystogenesis, a hypothesis further supported by the observed genetic interaction with Hnf4α. It would be interesting to see if perturbing the metabolic context could turn the early-onset into a late-onset model in animals induced before P12. It also remains to be shown that metabolic changes play a role in the late onset form of the disease.

In conclusion, the present comprehensive systems biology approach provided important insights into PKD biology and kidney maturation. The data suggest that Pkd1-cystogenesis does not require/cause developmental arrest, and occurs in the context of gene networks essentially similar to those that regulate/maintain normal kidney morphology/function. We also propose that postnatal kidney maturation is accompanied by changes in metabolic pathways that are likely to be modifiers of Pkd1-cystogenesis and could underlie the differences in the kinetics of cyst formation in early- or late-onset disease models. Finally, we show that Hnf4α is a modifier of Pkd1-cystogenesis.


Ethics Statement

All studies were performed using protocols approved by the JHU and NIH Animal Care and Use Committee, and mice were kept and cared in pathogen-free animal facilities accredited by the American Association for the Accreditation of Laboratory Animal Care and meet federal (NIH) guidelines for the humane and appropriate care of laboratory animal.


Fifth-generation C57/BL6 Pkd1cko mice were crossed to fifth-generation C57/BL6 tamoxifen-Cre (B6.Cg-Tg(Cre/Esr1)5Amc/J mice (stock 004682), Jackson Laboratories) and C57/BL6 congenic B6.129S4-Gt(ROSA)26Sortm1Sor/J (stock 003474, Jackson Laboratories) to produce the mice used in these studies. The Pkd1cko thus obtained were bred to Hnf4αcko mice (B6.129X1(FVB)-Hnf4αtm1.1Gonz/J (stock 004665, Jackson Laboratories). Cre recombinase activity was induced by intraperitoneal injection of tamoxifen (10 mg/40 g) in corn oil (Sigma-Aldrich) in nursing moms of mice<10 days of age. Mice were euthanized by isofluorane treatment followed by cervical dislocation.

Histology and Cystic Index

Specimens were fixed in 4% paraformaldehyde buffered solution, pH 7.4 at 4°C overnight, washed in PBS for 2 h, dehydrated in 50% ethanol for 2 h and stored in 70% ethanol at room temperature. The kidneys were cut in half along the longitudinal axis, embedded in paraffin and sectioned in 5-µm slices for hematoxylin and eosin staining. To calculate the cystic index, a composite image of a longitudinal midline kidney section was assembled using Axiovision (Zeiss), and the total kidney and cystic areas were measured using ImageJ [51]. Statistical analysis was performed using Student's t-test.

mRNA and microRNA Profiling

Total RNA was isolated from kidneys using Trizol reagent (Invitrogen). For mRNA studies, a subsequent step of RNA isolation using RNeasy plus kit was performed (Qiagen). Illumina's MouseRef-8 v1.0 or v2.0 BeadChip expression arrays with sample processing performed by the Johns Hopkins Bayview Medical Campus Genomics Core. For microRNA expession profiling, Agilent miRNA arrays were used with the Johns Hopkins Medical Institute microarray core (

microRNA real time PCR amplification was performed using TaqMan MicroRNA reverse transcription kit (4366596, Applied Biosystems), and the TaqMan microRNA assays has-miR-21, mmu-miR-31, has-miR-15a, normalized to microRNA snoRNA 202 control (respectively, RT 397, RT 185, RT 389, RT 1232; Applied Biosystems).

Microarray Data Analysis

Gene expression data were normalized using software provided by the Bioconductor project [52]. Briefly, we imported gene expression data using the lumi package, followed by preprocessing using variance stabilization transformation and quantile normalization [53], [54]. The data were filtered to include only probes with detection call p value<0.05 in at least one of the arrays and COMBAT software employed to remove batch effects [55]. When combining datasets of the two different Illumina array versions (v1.0 and v2.0), only probes present in both versions were included. For the microRNA data, quantile-normalization was applied. For both mRNA and microRNA normalized data, Partek was used to obtain principal component analysis and heatmap plots, and to identify differentially expressed probes/genes using ANOVA-based methods and fdr multiple comparison correction. For meta-analysis of published gene expression data, CEL files of experiments performed using Affymetrix Mouse Genome 430 2.0 arrays (platform GPL1261) were downloaded from GEO (, imported into Partek using RMA, followed by quantile normalization. All microarray data have been uploaded to the GEO database (Accession GSE32586).

Weighted Gene Co-Expression Network Analysis

For weighted gene co-expression network analysis (WGCNA) [56], the WGCNA R package was used [11]. Briefly, soft thresholding powers were chosen based on the approximate scale-free topology criterion [56], and applied blockwise network construction and module detection to the normalized expression matrix. We then correlated the modules with age and/or mutant status.

For comparative network analysis, multiSetMEs [11] was used to identify consensus modules for the 4 experimental groups: P12-mutant, P12-control, P14-mutant and P14-control, and to determine module preservation and quantify eigengene correlations [17].

Pathway Analysis

Genomatix Software Suite (Genomatix Inc.) was used to identify gene ontology, and pathway enrichment. To build knowledge-based networks, Ingenuity Pathway Analysis was used (IPA; Ingenuity Systems). Briefly, matrices were generated with fold-change and q-value for each of the comparisons of interest (i.e. age and mutant status) and considered genes with more than 1.2 fold change and q<0.05 as network eligible molecules. IPA was then used to screen the Ingenuity Knowledge Base (January 2011 release) for reported interactions involving these genes, to identify networks that maximize connectivity and to score them based on the number of network eligible molecules they contain. The network score corresponds roughly to –log10 (p value).

Urinary Metabolomics

Urine samples were collected at the time of euthanasia, diluted with 20 volumes of water and spun at 14,000× g for 10 min at 4C. The supernatant was transferred to an autosampler tube and analyzed by ultraperformance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight mass spectrometry. MarkerLynx software was used to align and deconvolute the mass chromatographic data and to generate a data matrix consisting of peak areas corresponding to a unique m/z and retention time. Statistical analysis was carried out using Partek, employing unpaired t-test comparing cre positive and negative animals, and partial least square (PLS) analysis. The relevant m/z to KEGG ids [57] were identified by searching the Scripps Center for Metabolomics Database with 5 ppm accuracy and possible modifications (+H, +NH4, +Na, +H-2H2O, +H-H2O in the positive mode; −H, −H2O-H, +Na-2H, +Cl, +K-2H in the negative mode) [58]. Verification of acetylcarnitine (m/z 204.123) was obtained by comparing fragmentation patterns of urine samples with authentic standard by tandem mass spectrometry. For generation of MS/MS fragments, the mass spectrometer collision energy was ramped from 6 to 40 V. For pathway enrichment analysis, Ingenuity Pathway Analysis was used.

Supporting Information

Attachment 1

Attachment 2

Attachment 3

Attachment 4

Attachment 5

Attachment 6

Attachment 7

Attachment 8

Attachment 9

Attachment 10

Attachment 11

Attachment 12

Attachment 13

Attachment 14

Attachment 15

Attachment 16

Attachment 17


1. TorresV, HarrisP, PirsonY (2007) Autosomal dominant polycystic kidney disease. Lancet 369: 1287–1301.

2. MenezesL, GerminoG (2009) Polycystic kidney disease, cilia, and planar polarity. Methods Cell Biol 94: 273–297.

3. PiontekK, HusoD, GrinbergA, LiuL, BedjaD, et al. (2004) A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol 15: 3035–3043.

4. PiontekK, MenezesL, Garcia-GonzalezM, HusoD, GerminoG (2007) A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 13: 1490–1495.

5. Lantinga-van LeeuwenIS, LeonhardWN, van der WalA, BreuningMH, de HeerE, et al. (2007) Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Hum Mol Genet 16: 3188–3196.

6. DavenportJR, WattsAJ, RoperVC, CroyleMJ, van GroenT, et al. (2007) Disruption of intraflagellar transport in adult mice leads to obesity and slow-onset cystic kidney disease. Curr Biol 17: 1586–1594.

7. VerdeguerF, Le CorreS, FischerE, CallensC, GarbayS, et al. (2010) A mitotic transcriptional switch in polycystic kidney disease. Nat Med 16: 106–110.

8. FalkG (1955) Maturation of renal function in infant rats. Am J Physiol 181: 157–170.

9. AbuazzaG, BeckerA, WilliamsS, ChakravartyS, TruongH, et al. (2006) Claudins 6, 9, and 13 are developmentally expressed renal tight junction proteins. Am J Physiol Renal Physiol 291: F1132–1141.

10. BeckerA, ZhangJ, GoyalS, DwarakanathV, AronsonP, et al. (2007) Ontogeny of NHE8 in the rat proximal tubule. Am J Physiol Renal Physiol 293: F255–261.

11. LangfelderP, HorvathS (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9: 559.

12. BarabásiAL, GulbahceN, LoscalzoJ (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12: 56–68.

13. GonzalezFJ (2008) Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet 23: 2–7.

14. LiX, MagenheimerBS, XiaS, JohnsonT, WallaceDP, et al. (2008) A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 14: 863–868.

15. ChapmanAB, TorresVE, PerroneRD, SteinmanTI, BaeKT, et al. (2010) The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 5: 102–109.

16. TorresV, WangX, QianQ, SomloS, HarrisP, et al. (2004) Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363–364.

17. LangfelderP, HorvathS (2007) Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol 1: 54.

18. OldhamM, HorvathS, GeschwindD (2006) Conservation and evolution of gene coexpression networks in human and chimpanzee brains. Proc Natl Acad Sci U S A 103: 17973–17978.

19. PastorelliL, WellsS, FrayM, SmithA, HoughT, et al. (2009) Genetic analyses reveal a requirement for Dicer1 in the mouse urogenital tract. Mamm Genome 20: 140–151.

20. PandeyP, BrorsB, SrivastavaP, BottA, BoehnS, et al. (2008) Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics 9: 624.

21. PandeyP, QinS, HoJ, ZhouJ, KreidbergJA (2011) Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease. BMC Syst Biol 5: 56.

22. LeeS, MasyukT, SplinterP, BanalesJ, MasyukA, et al. (2008) MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 118: 3714–3724.

23. AllenE, PiontekK, Garrett-MayerE, Garcia-GonzalezM, GorelickK, et al. (2006) Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors. Hum Mol Genet 15: 11–21.

24. TakiarV, NishioS, Seo-MayerP, KingJD, LiH, et al. (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108: 2462–2467.

25. Tanguay RM, Marie L, Markus G, A MG (2011) Hypertyrosinemia. In: Valle, Beaudet, Vogelstein, Kinzler, Antonarakis, et al.., editors. Scriver's Online Metabolic and Molecular Bases of Inherited Disease.

26. YamaguchiT, PellingJ, RamaswamyN, EpplerJ, WallaceD, et al. (2000) cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460–1471.

27. YamaguchiT, WallaceD, MagenheimerB, HempsonS, GranthamJ, et al. (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279: 40419–40430.

28. ChalmersRA, RoeCR, StaceyTE, HoppelCL (1984) Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr Res 18: 1325–1328.

29. BöhmN, UyJ, KiesslingM, LehnertW (1982) Multiple acyl-CoA dehydrogenation deficiency (glutaric aciduria type II), congenital polycystic kidneys, and symmetric warty dysplasia of the cerebral cortex in two newborn brothers. II. Morphology and pathogenesis. Eur J Pediatr 139: 60–65.

30. HussonH, ManavalanP, AkmaevV, RussoR, CookB, et al. (2004) New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies. Genomics 84: 497–510.

31. SongX, Di GiovanniV, HeN, WangK, IngramA, et al. (2009) Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18: 2328–2343.

32. ChenW, TzengY, LiH (2008) Gene expression in early and progression phases of autosomal dominant polycystic kidney disease. BMC Res Notes 1: 131.

33. ChenWS, ManovaK, WeinsteinDC, DuncanSA, PlumpAS, et al. (1994) Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev 8: 2466–2477.

34. LiJ, NingG, DuncanSA (2000) Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. Genes Dev 14: 464–474.

35. ParvizF, MatulloC, GarrisonWD, SavatskiL, AdamsonJW, et al. (2003) Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 34: 292–296.

36. BattleMA, KonopkaG, ParvizF, GagglAL, YangC, et al. (2006) Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A 103: 8419–8424.

37. GarrisonWD, BattleMA, YangC, KaestnerKH, SladekFM, et al. (2006) Hepatocyte nuclear factor 4alpha is essential for embryonic development of the mouse colon. Gastroenterology 130: 1207–1220.

38. HayhurstG, LeeY, LambertG, WardJ, GonzalezF (2001) Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 21: 1393–1403.

39. AhnSH, ShahYM, InoueJ, MorimuraK, KimI, et al. (2008) Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis 14: 908–920.

40. RheeJ, GeH, YangW, FanM, HandschinC, et al. (2006) Partnership of PGC-1alpha and HNF4alpha in the regulation of lipoprotein metabolism. J Biol Chem 281: 14683–14690.

41. AdamsonAW, SuchankovaG, RufoC, NakamuraMT, Teran-GarciaM, et al. (2006) Hepatocyte nuclear factor-4alpha contributes to carbohydrate-induced transcriptional activation of hepatic fatty acid synthase. Biochem J 399: 285–295.

42. DankelSN, HoangT, FlågengMH, SagenJV, MellgrenG (2010) cAMP-mediated regulation of HNF-4alpha depends on the level of coactivator PGC-1alpha. Biochim Biophys Acta 1803: 1013–1019.

43. HayhurstGP, Strick-MarchandH, MuletC, RichardAF, MorosanS, et al. (2008) Morphogenetic competence of HNF4 alpha-deficient mouse hepatic cells. J Hepatol 49: 384–395.

44. KanazawaT, IchiiO, OtsukaS, NamikiY, HashimotoY, et al. (2011) Hepatocyte nuclear factor 4 alpha is associated with mesenchymal-epithelial transition in developing kidneys of C57BL/6 mice. J Vet Med Sci 73: 601–607.

45. VincentSD, RobertsonEJ (2004) Targeted insertion of an IRES Cre into the Hnf4alpha locus: Cre-mediated recombination in the liver, kidney, and gut epithelium. Genesis 39: 206–211.

46. TaylorSL, GantiS, BukanovNO, ChapmanA, FiehnO, et al. (2010) A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol 298: F909–922.

47. AbbissH, MakerGL, GummerJ, SharmanMJ, PhillipsJK, et al. (2012) Development of a non-targeted metabolomics method to investigate urine in a rat model of polycystic kidney disease. Nephrology (Carlton) 17: 104–110.

48. HsuPP, SabatiniDM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703–707.

49. BolettaA (2009) Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2: 6.

50. WeiQ, BhattK, HeH, MiQ, HaaseV, et al. (2010) Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 21: 756–761.

51. Rasband WS (1997–2011) Imagej, U.S. National Institues of Health, Bethesda, MD, USA.

52. GentlemanR, CareyV, BatesD, BolstadB, DettlingM, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.

53. DuP, KibbeW, LinS (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547–1548.

54. LinS, DuP, HuberW, KibbeW (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36: e11.

55. JohnsonW, LiC, RabinovicA (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118–127.

56. ZhangB, HorvathS (2005) A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 4: Article17.

57. KanehisaM, GotoS (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27–30.

58. SmithCA, O'MailleG, WantEJ, QinC, TraugerSA, et al. (2005) METLIN: a metabolite mass spectral database. Ther Drug Monit 27: 747–751.

Genetika Reprodukční medicína

Článek vyšel v časopise

PLOS Genetics

2012 Číslo 11

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Zvyšte si kvalifikaci online z pohodlí domova

Kožní toxicita cílené terapie inhibitory EGFR a VEGF
nový kurz
Autoři: MUDr. Karolína Svobodová

Jak na psoriázu v každodenní ambulantní praxi?
Autoři: MUDr. Jan Šternberský, Ph. D.

Biologická léčba Crohnovy nemoci
Autoři: MUDr. Přemysl Falt, Ph.D.

Pacient na antikoagulační léčbě v akutní situaci
Autoři: MUDr. Jana Michalcová

Kopřivka a její terapie
Autoři: MUDr. Petra Brodská

Všechny kurzy
Kurzy Doporučená témata Časopisy
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se